Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma
- 7 of 10 r/r NHL patients achieved complete response (70% CR rate) following treatment with NKX019 monotherapy at 1 billion and 1.5 billion CAR NK cells per dose in the Phase 1 dose escalation study
- Data demonstrate potential for redosing of allogeneic CD19 CAR NK to deepen response or restore response post-relapse
- Majority of patients achieved CR after a single cycle of NKX019
- Early safety data support potential of allogeneic CD19 CAR NK to be administered on outpatient basis
- No neurotoxicity / ICANS, graft versus host disease (GvHD), or > Gr3 cytokine release syndrome (CRS)
- 40% of eligible patients received NKX019 in the outpatient setting after first cycle